Scholar Rock Faces Regulatory Concerns at Catalent Facility

Scholar Rock Holding ( (SRRK) ) has shared an update.

On October 10, 2025, Scholar Rock Holding Corporation was informed by Novo Nordisk that the U.S. Food and Drug Administration has classified the inspection of Catalent Indiana, LLC as ‘official action indicated’ following a Form FDA 483 issued on July 14, 2025. This classification could have implications for Scholar Rock’s operations and its stakeholders, as it suggests regulatory concerns at a facility owned by Novo Nordisk.

The most recent analyst rating on (SRRK) stock is a Buy with a $53.00 price target. To see the full list of analyst forecasts on Scholar Rock Holding stock, see the SRRK Stock Forecast page.

Spark’s Take on SRRK Stock

According to Spark, TipRanks’ AI Analyst, SRRK is a Neutral.

Scholar Rock’s overall stock score reflects significant challenges due to financial underperformance, including a lack of revenue and ongoing losses. Despite these issues, positive strides in its SMA program and strategic leadership changes indicate potential for future growth. Mixed technical indicators and a weak valuation further moderate the outlook.

To see Spark’s full report on SRRK stock, click here.

More about Scholar Rock Holding

Average Trading Volume: 2,287,936

Technical Sentiment Signal: Buy

Current Market Cap: $3.79B

For detailed information about SRRK stock, go to TipRanks’ Stock Analysis page.